Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment
NCT ID: NCT02204332
Last Updated: 2014-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
38 participants
INTERVENTIONAL
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.
NCT01067053
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
NCT03542877
caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.
NCT06171854
Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients
NCT00875771
DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
NCT00024401
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cabazitaxel
Cabazitaxel at a dose of 25 mg / m² in a 5% dextrose or 0.9% NaCl intravenously over 1 hour, every 3 weeks (1 cycle).
Besides, patient will be treated with BSC.
Cabazitaxel
Best Supportive Care
Best Supportive Care (BSC), with evaluations every 3 weeks (1 cycle).
Best Supportive Care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cabazitaxel
Best Supportive Care
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and women aged ≥ 18 years.
* Patients with histologically confirmed metastatic advanced colorectal cancer without the possibility of potentially curative treatment.
* Patients with a life expectancy more than three months.
* Patients with advanced colorectal cancer in progression after receiving standard treatment.
* Patients with grade 0-2 functional status, according to Eastern Cooperative Oncology Group (ECOG).
* Patients with evaluable tumor by RECIST criteria.
* Patients recovered and with a degree less than or equal to 1, or baseline of all important pre-treatment-related AEs (excluding alopecia).
* Ability and willingness of the patient to consent to participation in the study.
* Ability to understand and comply with study procedures.
Exclusion Criteria
* Inadequate marrow reserve, within 7 days prior to randomization:
* absolute neutrophil count \<1.5 x 109 / L
* Hemoglobin \<9.0 g / dL
* Platelet count \<100 x 109 / L
* Inadequate liver function within 7 days prior to randomization:
* AST (SGOT) and ALT (SGPT)\> 3.0 x ULN or 5\> x ULN in case of abnormal liver function due to underlying liver metastases.
* Alkaline phosphatase\> 3 × ULN (or 5 times the ULN if due to underlying liver metastases).
* Total bilirubin\> 1.5 x ULN.
* Previous history of other malignancy, except for skin basal or squamous cell cancer with proper treatment, or in situ cervical cancer, or other cancers, in which the patient has been free of the disease in the last 5 years.
* Simultaneous treatment with concomitant anticancer therapy.
* History of brain metastases, uncontrolled compression of spinal cord, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease pathologies.
* Acquired Immunodeficiency Syndrome (AIDS-related diseases) or human immunodeficiency virus (HIV) or conditions requiring antiretroviral therapy virus.
* symptomatic grade ≥ 2 peripheral sensory neuropathy, according to NCI-CTCAE v4.0.
* Any severe acute or chronic medical condition that may affect the patient's ability to participate in the study, or may lead to unacceptable security risks and non-compliance with protocol procedures or may interfere with the interpretation of the study results.
* Pregnant women or who are breastfeeding. Pregnancy assessment will be conducted by a test serum or urine during the 7 days prior to randomization.
* Patient (male or female) of reproductive age who still disagrees with the use of effective contraception during the treatment period and for at least 3 months after completion of the treatment period of the study. The definition of "effective method of birth control" is the opinion of the investigator.
* Participation in another clinical trial with an investigational drug and / or an investigational drug as adjunctive therapy within 30 days prior to randomization.
* Concomitant treatment with prohibited drugs as potent inhibitors or inducers of cytochrome P450 3A4.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundación Ramón Domínguez
OTHER
Hospital Clinico Universitario de Santiago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rafael Lopez Lopez
MD,PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rafael López López, MD, PhD
Role: STUDY_CHAIR
Hospital Clinico de Santiago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital German Trias i Pujol
Badalona, , Spain
Hospital Arnau de Vilanova
Lleida, , Spain
Hospital Ramón y Cajal
Madrid, , Spain
Hospital Carlos Haya
Málaga, , Spain
CHU de Orense
Ourense, , Spain
Hospital Clinico de Santiago
Santiago de Compostela, , Spain
Hospital General de Valencia
Valencia, , Spain
Hospital Miguel Servet
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RLL-CAB-2011-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.